Jesùs Peña-Martin

Dr. Jesùs Peña-Martin

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2023 in ACS Applied Materials & Interfaces
Verified
Journal Article
Open access
PGPablo Graván
Pablo Graván
JPJesùs Peña-Martin
Jesùs Peña-Martin
JAJulia López de Andrés
Julia López de Andrés
MPMaría Pedrosa
María Pedrosa
MVMartín Villegas-Montoya
Martín Villegas-Montoya
PSPaola Sánchez-Moreno
Paola Sánchez-Moreno
Nanotechnological platforms offer advantages over conventional therapeutic and diagnostic modalities. However, the efficient biointerfacing of nanomaterials for biomedical applications remains challenging. In recent years, nanoparticles (NPs) with different coatings have been developed to reduce nonspecific interactions, prolong circulation time, and improve therapeutic outcomes. This study aims to compare various NP coatings to enhance surface engineering for more effective nanomedicines. We prepared and characterized polystyrene NPs with different coatings of poly(ethylene glycol), bovine serum albumin, chitosan, and cell membranes from a human breast cancer cell line. The coating was found to affect the colloidal stability, adhesion, and elastic modulus of NPs. Protein corona formation and cellular uptake of NPs were also investigated, and a 3D tumor model was employed to provide a more realistic representation of the tumor microenvironment. The prepared NPs were found to reduce protein adsorption, and cell-membrane-coated NPs showed significantly higher cellular uptake. The secretion of proinflammatory cytokines in human monocytes after incubation with the prepared NPs was evaluated. Overall, the study demonstrates the importance of coatings in affecting the behavior and interaction of nanosystems with biological entities. The findings provide insight into bionano interactions and are important for the effective implementation of stealth surface engineering designs.

19 November 2020 in Cancers
Verified
Journal Article
Open access
PDF file
APAndrea Pisano
Andrea Pisano
CGCarmen Griñán-Lisón
Carmen Griñán-Lisón
Cristiano FaraceCristiano Farace
Cristiano Farace
Giovanni FioritoGiovanni Fiorito
Giovanni Fiorito
GFGrazia Fenu
Grazia Fenu
Roberto MadedduRoberto Madeddu
Roberto Madeddu
Colorectal cancer (CRC) is the third most frequent cancer worldwide and the second cause of cancer deaths. Increasing evidences supports the idea that the poor prognosis of patients is related to the presence of cancer stem cells (CSCs), a cell population able to drive cancer recurrence and metastasis. The deregulation of microRNAs (miRNAs) plays a role in the formation of CSC. We investigated the role of hsa-miR-486-5p (miR-486-5p) in CRC, CSCs, and metastasis, in order to reach a better understanding of the biomolecular and epigenetic mechanisms mir-486-5p-related. The expression of miR-486-5p was investigated in three different matrices from CRC patients and controls and in CSCs obtained from the CRC cell lines HCT-116, HT-29, and T-84. In the human study, miR-486-5p was up-regulated in serum and stool of CRC patients in comparison with healthy controls but down-regulated in tumor tissue when compared with normal mucosa. miR-486-5p was also down-regulated in the sera of metastatic patients. In vitro, miR-486-5p was down-regulated in CSC models and it induced an inhibitory effect on stem factors and oncogenes in the main pathways of CSCs. Our results provide a step forward in understanding the role of mir-486-5p in CRC and CSC, and suggest that further studies are needed to investigate its diagnostic and prognostic power, possibly in combination with other biomarkers.

12 February 2014 in Wilhelm Roux' Archiv für Entwicklungsmechanik der Organismen
Verified
Journal Article
Closed access
PDF file
MOMarta Bastos Oliveira
Marta Bastos Oliveira
SLSimon Eckerström Liedholm
Simon Eckerström Liedholm
JLJordi Estefa Lopez
Jordi Estefa Lopez
ALAnnalena A. Lochte
Annalena A. Lochte
MPMagdalena Pazio
Magdalena Pazio
RJRalf Janssen
Ralf Janssen

26 September 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Houria BoulaizHouria Boulaiz
Houria Boulaiz
YJYaiza Jimenez
Yaiza Jimenez
FFFrancisco Franco-Montalbán
Francisco Franco-Montalbán
JPJesùs Peña-Martin
Jesùs Peña-Martin
ACAna Conejo-García
Ana Conejo-García
MCMaría Dora Carrión
María Dora Carrión
Background/Objectives: Targeted cancer therapies increasingly rely on modulating specific cell death pathways and kinase signaling. Due to their structural versatility and potential to induce mechanistically distinct cytotoxic responses, benzoxazine–purine hybrids represent a promising scaffold for anticancer drug development. The objective of this study was to design and evaluate novel benzoxazine–purine derivatives for their antiproliferative activity and elucidate their underlying mechanisms of action. Methods: A series of benzoxazine–purine compounds was synthesized via a modular and efficient approach. The synthetic route involved a one-pot cyclization of substituted 2-aminophenols with epichlorohydrin, followed by tosylation and subsequent Mitsunobu coupling with halogenated purines. Their antiproliferative activity was assessed in MCF-7 (breast) and HCT-116 (colon) cancer cell lines using MTT assays. Selected compounds were evaluated further for kinase inhibition, effects on the cell cycle, membrane integrity (Annexin V/PI staining), ultrastructural changes (SEM), and caspase activation (Western blot). In silico ADMET profiling was also performed. Results: Compounds 9 and 12 exhibited the most potent antiproliferative activity, with low micromolar IC50 values. Compound 12 showed dual HER2/JNK1 kinase inhibition and induced caspase-8-dependent pyroptosis-like cell death, characterized by membrane rupture and inflammatory features. In contrast, compound 8 lacked kinase inhibition and promoted S-phase arrest with apoptotic-like morphology. Both compounds demonstrated favorable physicochemical and ADMET profiles, including high intestinal absorption and an absence of mutagenicity. Conclusions: The rational design of benzoxazine–purine hybrids resulted in the discovery of compounds with distinct mechanisms of action. Compound 12 induces inflammatory cell death by modulating kinases, while compound 9 acts through a kinase-independent apoptotic pathway. These results underscore the therapeutic potential of scaffold-based diversification for developing targeted anticancer agents.